Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer (Q37357924)

From Wikidata

Jump to navigation Jump to search

scientific article published on 23 December 2008

edit

Language	Label	Description	Also known as
English	Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer	scientific article published on 23 December 2008

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19107109

retrieved

19 August 2017

review article

1 reference

stated in

Europe PubMed Central

title

Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19107109

retrieved

19 August 2017

main subject

systemic therapy

1 reference

based on heuristic

inferred from title

trastuzumab

1 reference

based on heuristic

inferred from title

breast cancer

1 reference

based on heuristic

inferred from title

author

Gabriella Mariani

series ordinal

1

object named as

Gabriella Mariani

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19107109

retrieved

19 August 2017

Luca Gianni

series ordinal

4

object named as

Luca Gianni

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19107109

retrieved

19 August 2017

author name string

Angelica Fasolo

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19107109

retrieved

19 August 2017

Elena De Benedictis

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19107109

retrieved

19 August 2017

publication date

23 December 2008

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19107109

retrieved

19 August 2017

published in

Nature Clinical Practice Oncology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19107109

retrieved

19 August 2017

volume

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19107109

retrieved

19 August 2017

issue

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19107109

retrieved

19 August 2017

page(s)

93-104

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19107109

retrieved

19 August 2017

cites work

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNCPONC1298

retrieved

21 January 2018

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNCPONC1298

retrieved

21 January 2018

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNCPONC1298

retrieved

21 January 2018

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The cost of life: should it matter to doctors?

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGF-ERBB signalling: towards the systems level

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab in the treatment of breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TEACH: Tykerb evaluation after chemotherapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ErbB2 is essential in the prevention of dilated cardiomyopathy.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Requirement for neuregulin receptor erbB2 in neural and cardiac development

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Herceptin and the heart--a molecular modifier of cardiac failure

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose scheduling--Herceptin

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib: current status and future directions in breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical cardiac tolerability of trastuzumab

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resistance to trastuzumab: a necessary evil or a temporary challenge?

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19107109

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The "other" signaling of trastuzumab: antibodies are immunocompetent drugs

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNCPONC1298

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1038/NCPONC1298

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19107109

retrieved

19 August 2017

PubMed publication ID

19107109

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19107109

retrieved

19 August 2017

ResearchGate publication ID

23688777

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37357924&oldid=1966905033"